205 related articles for article (PubMed ID: 15141012)
1. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
2. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
Smythe WR; Mohuiddin I; Ozveran M; Cao XX
J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
[TBL] [Abstract][Full Text] [Related]
3. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
Hopkins-Donaldson S; Cathomas R; Simões-Wüst AP; Kurtz S; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Int J Cancer; 2003 Aug; 106(2):160-6. PubMed ID: 12800189
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
Varin E; Denoyelle C; Brotin E; Meryet-Figuière M; Giffard F; Abeilard E; Goux D; Gauduchon P; Icard P; Poulain L
Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
[TBL] [Abstract][Full Text] [Related]
7. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma.
Mohiuddin I; Cao X; Fang B; Nishizaki M; Smythe WR
Cancer Gene Ther; 2001 Aug; 8(8):547-54. PubMed ID: 11571532
[TBL] [Abstract][Full Text] [Related]
8. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
Cao XX; Mohuiddin I; Ece F; McConkey DJ; Smythe WR
Am J Respir Cell Mol Biol; 2001 Nov; 25(5):562-8. PubMed ID: 11713097
[TBL] [Abstract][Full Text] [Related]
10. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
11. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
[TBL] [Abstract][Full Text] [Related]
12. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
13. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
[TBL] [Abstract][Full Text] [Related]
15. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Mol Cancer Ther; 2004 Feb; 3(2):169-78. PubMed ID: 14985457
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL.
Cao XX; Mohuiddin I; Chada S; Mhashilkar AM; Ozvaran MK; McConkey DJ; Miller SD; Daniel JC; Smythe WR
Mol Med; 2002 Dec; 8(12):869-76. PubMed ID: 12606823
[TBL] [Abstract][Full Text] [Related]
17. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
[TBL] [Abstract][Full Text] [Related]
18. Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma.
Cao X; Rodarte C; Zhang L; Morgan CD; Littlejohn J; Smythe WR
Cancer Biol Ther; 2007 Feb; 6(2):246-52. PubMed ID: 17224645
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
